138 related articles for article (PubMed ID: 7755383)
1. [A controlled study of AO-90, a methionine-free intravenous amino acid solution, in combination with 5-fluorouracil and mitomycin C in advanced gastric cancer patients (surgery group evaluation)].
Taguchi T; Kosaki G; Onodera T; Endo M; Nakagawara G; Sano K; Kaibara N; Kakegawa T; Nakano S; Kurihara M
Gan To Kagaku Ryoho; 1995 May; 22(6):753-64. PubMed ID: 7755383
[TBL] [Abstract][Full Text] [Related]
2. [A controlled study of AO-90, a methionine-free intravenous amino acid solution, in combination with 5-fluorouracil and mitomycin C in advanced gastric cancer patients (internal medicine group evaluation)].
Kitamura S; Ohtani T; Kurihara M; Kosaki G; Akazawa S; Sasaki T; Takahashi H; Nakano S; Tokunaga K
Gan To Kagaku Ryoho; 1995 May; 22(6):765-75. PubMed ID: 7755384
[TBL] [Abstract][Full Text] [Related]
3. [Quality of life in patients with advanced gastric cancer receiving AO-90, a methionine-free intravenous amino acid solution, with 5-fluorouracil and mitomycin C].
Kurihara M; Kosaki G; Taguchi T; Akazawa S; Sasaki T; Takahashi H; Onodera T; Endo M; Nakagawara G; Sano K
Gan To Kagaku Ryoho; 1995 Jun; 22(7):911-23. PubMed ID: 7793997
[TBL] [Abstract][Full Text] [Related]
4. [Clinical evaluation of anticancer effect of methionine-depleting total parenteral nutrition with 5-fluorouracil and/or mitomycin C].
Goseki N; Maruyama M; Nagai K; Kando F; Endo M; Shimoju K; Wada Y
Gan To Kagaku Ryoho; 1995 Jul; 22(8):1028-35. PubMed ID: 7611753
[TBL] [Abstract][Full Text] [Related]
5. [Early phase II study of the combined use of AO-90 methionine-free amino acid solution and anticancer agents (5-FU and MMC) in patients with advanced and recurrent gastrointestinal cancer. AO-90 Study group].
Sugihara K; Auther C; Mori S; Nishihira T; Matsumoto T; Kawachi S; Ishikawa M; Takahashi M; Nakajima T; Kosaki G
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2405-13. PubMed ID: 2124434
[TBL] [Abstract][Full Text] [Related]
6. Sequence-dependence of cisplatin and 5-fluorouracil in advanced and recurrent gastric cancer.
Koizumi W; Kurihara M; Hasegawa K; Chonan A; Kubo Y; Maekawa R; Iwasaki R; Sasai T; Fukuyama Y; Ishikawa K; Miyoshi K; Yasutake K; Hayakawa M
Oncol Rep; 2004 Sep; 12(3):557-61. PubMed ID: 15289837
[TBL] [Abstract][Full Text] [Related]
7. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma.
Takada T; Amano H; Yasuda H; Nimura Y; Matsushiro T; Kato H; Nagakawa T; Nakayama T;
Cancer; 2002 Oct; 95(8):1685-95. PubMed ID: 12365016
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1.
Nashimoto A; Nakajima T; Furukawa H; Kitamura M; Kinoshita T; Yamamura Y; Sasako M; Kunii Y; Motohashi H; Yamamoto S;
J Clin Oncol; 2003 Jun; 21(12):2282-7. PubMed ID: 12805327
[TBL] [Abstract][Full Text] [Related]
9. Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Kondo K; Kobayashi M; Kojima H; Hirabayashi N; Kataoka M; Araki K; Matsui T; Takiyama W; Miyashita Y; Nakazato H; Nakao A; Sakamoto J
Jpn J Clin Oncol; 2005 Jun; 35(6):332-7. PubMed ID: 15961435
[TBL] [Abstract][Full Text] [Related]
10. [Prospective randomized trial comparing modified FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus 5-FU alone for the treatment of non-resectable pancreatic and biliary tract carcinomas (the 1st trial in non-resectable patients). Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract].
Takada T; Kato H; Sasaki M; Matsushiro T; Yamauchi H; Kajihara T; Watanabe G; Hanaue H; Yoshida K; Shimizu T
Gan To Kagaku Ryoho; 1992 Aug; 19(9):1295-301. PubMed ID: 1503483
[TBL] [Abstract][Full Text] [Related]
11. [Randomized multicenter trial of sequential methotrexate and 5-fluorouracil versus 5-fluorouracil alone in advanced gastric cancer].
Sasaki T; Ota K; Ibayashi J; Sakata Y; Matsuoka T; Ishikawa M; Wakui A; Ogoshi K; Akazawa S; Sakai Y
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2545-55. PubMed ID: 2673045
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of mitomycin C, cisplatin and 5-fluorouracil for advanced and recurrent gastric cancer.
Kikuyama S; Inada T; Oyama R; Ogata Y
Anticancer Res; 2002; 22(6B):3633-6. PubMed ID: 12552968
[TBL] [Abstract][Full Text] [Related]
13. [Methionine-deprived amino acid solution-induced biochemical modulation of 5-FU and augmentation of the antitumor activity].
Maeta M; Kaibara N; Sugihara K
Gan To Kagaku Ryoho; 1992 May; 19(5):618-23. PubMed ID: 1580636
[TBL] [Abstract][Full Text] [Related]
14. A combination chemotherapy of 5-fluorouracil and cisplatin against advanced gastric cancer.
Imada T; Sairenji M; Suda T; Yamamoto Y; Amano T; Motohashi H
Hepatogastroenterology; 1999; 46(25):594-600. PubMed ID: 10228867
[TBL] [Abstract][Full Text] [Related]
15. [The effect of combination chemotherapy to adapted to chronotherapy with 5-fluorouracil, leucovorin, mitomycin C and cisplatin in patients with gastric or colorectal cancer].
Kamoshita N; Yokomori T; Iesato H; Ohya T; Nagaoka H; Okabe T; Kato Y; Takeyoshi I; Ohwada S; Morishita Y
Gan To Kagaku Ryoho; 2000 May; 27(5):711-6. PubMed ID: 10832439
[TBL] [Abstract][Full Text] [Related]
16. Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma.
Chung YS; Yamashita Y; Inoue T; Matsuoka T; Nakata B; Onoda N; Maeda K; Sawada T; Kato Y; Shirasaka T; Sowa M
Cancer; 1997 Jul; 80(1):1-7. PubMed ID: 9210702
[TBL] [Abstract][Full Text] [Related]
17. [Postoperative adjuvant chemotherapy using NCS (neocarzinostatin) and 5-FU in the treatment of gastric cancer. First report--A comparison with the 5-year survival rate of patients undergoing combined therapy with MMC and 5-FU].
Yokomori T; Taniguchi T; Iesato H; Sakata Y; Watanabe T; Kawabe K
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3064-70. PubMed ID: 2960267
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy of continuous 5-FU infusion and low-dose cisplatin infusion for the treatment of advanced and recurrent gastric and colorectal adenocarcinomas.
Tsuji A; Morita S; Horimi T; Takasaki M; Takahashi I; Shirasaka T
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():528-34. PubMed ID: 10895205
[TBL] [Abstract][Full Text] [Related]
20. A combination immunochemotherapy of 5-fluorouracil, cisplatin, leucovorin, and OK-432 for advanced and recurrent gastric carcinoma.
Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Noguchi Y
Hepatogastroenterology; 2003; 50(54):2259-63. PubMed ID: 14696512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
